Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Surgical Resection of Melanoma Clear all
Active, not recruiting Phase 1 Interventional

A Study of LN-144 in People With Metastatic Melanoma to the Brain

NCT05640193
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Lifileucel (LN-144)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Terminated Phase 3 Interventional Results available

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

NCT00796445
View directory record Official record
Conditions
Melanoma
Interventions
GSK 2132231A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
74
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nanocytology Test to Evaluate Skin Cancer in High Risk Patients

NCT01905891
View directory record Official record
Conditions
Actinic Keratosis, Squamous Cell Carcinoma
Interventions
Superficial shave biopsy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 25, 2026, 10:54 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

NCT05488483
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Multispectral Optoacoustic Tomography Imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
3
States / cities
Montvale, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 2 Interventional

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

NCT06151847
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Biospecimen Collection, Cyclophosphamide, Echocardiography, Fludarabine, Interleukin-2, Lifileucel, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tumor Resection
Procedure · Drug · Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 3 Interventional

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

NCT00039000
View directory record Official record
Conditions
Malignant Melanoma
Interventions
HSPPC-96 or Oncophage
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

NCT05230186
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Tumor Biopsy
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • New Orleans, Louisiana • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

NCT03138161
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
Interventions
Trabectedin, Ipilimumab, Nivolumab
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 25, 2026, 10:54 PM EDT
Terminated No phase listed Observational

TEST: Registry for Endoscopic Head and Neck Surgery

NCT01412749
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

NCT00025181
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 3 Interventional Results available

A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

NCT01667419
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • California City, California • Hayward, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 25, 2026, 10:54 PM EDT
Active, not recruiting Phase 2 Interventional

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

NCT05111574
View directory record Official record
Conditions
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
142
States / cities
Auburn, California • Berkeley, California • Fremont, California + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

NCT05611229
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Nivolumab, Pembrolizumab, Dabrafenib+Trametinib, Ipilimumab+Nivolumab, Vemurafenib+Cobimetinib, Encorafenib+Binimetinib
Drug · Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 25, 2026, 10:54 PM EDT
Recruiting Phase 1Phase 2 Interventional

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

NCT07288112
View directory record Official record
Conditions
Refractory Melanoma
Interventions
DOC1021, Tumor resection, pIFN (peginterferon alfa-2a)
Biological · Procedure · Drug
Lead sponsor
Diakonos Oncology Corporation
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
8
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Terminated Phase 2 Interventional Results available

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

NCT01092728
View directory record Official record
Conditions
Melanoma
Interventions
Dasatinib, Surgical Resection
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth

NCT02613325
View directory record Official record
Conditions
Pigmented Skin Lesion, Melanoma
Interventions
Functional photoacoustic microscopy, Standard of care surgical excision, Single cell photoacoustic microscopy
Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 25, 2026, 10:54 PM EDT
Recruiting Phase 2 Interventional

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

NCT07621614
View directory record Official record
Conditions
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
Interventions
Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
13
States / cities
Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Withdrawn No phase listed Observational

Mohs Micrographic Surgery and Reconstruction in the Optum Insurance Claims Database

NCT04117373
View directory record Official record
Conditions
Skin Cancer, Mohs Micrographic Surgery, Interpolated Flap Repair
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Year to 99 Years
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 25, 2026, 10:54 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

NCT05002569
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 25, 2026, 10:54 PM EDT
Withdrawn Phase 2 Interventional

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

NCT03005639
View directory record Official record
Conditions
Stage IIIB-C Melanoma
Interventions
Vemurafenib and Cobimetinib
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational Results available

A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma

NCT01986712
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
St. Luke's Hospital and Health Network, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
4
States / cities
Tampa, Florida • Buffalo, New York • Bethlehem, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 25, 2026, 10:54 PM EDT
Active, not recruiting No phase listed Observational

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

NCT05736523
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 25, 2026, 10:54 PM EDT
Completed Not applicable Interventional Results available

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

NCT01886235
View directory record Official record
Conditions
Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 25, 2026, 10:54 PM EDT
Completed No phase listed Observational Results available

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

NCT05105100
View directory record Official record
Conditions
Melanoma, Advanced Melanoma
Interventions
Biopsy, Biospecimen Collection
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 25, 2026, 10:54 PM EDT